Drug intelligence / Profile preview

Aβ-SM

Development stage: Preclinical
Lead developer: Innovative California Biosciences International
Modality: Antibody-Based Therapeutics, Small Molecules

Overview

Aβ-SM is a preclinical blood-brain barrier penetrant anti-amyloid beta therapeutic being developed by Innovative California Biosciences International for Alzheimer's disease. It is described by the company as a SMART Molecule, a reduced-size antibody mimic designed to bind soluble amyloid-beta species and plaques in the brain, with the goal of promoting amyloid neutralization and clearance while achieving substantially greater brain penetration than conventional monoclonal antibodies.

Other names: amyloid-beta small moleculeamyloid-beta SMART Moleculeamyloid beta small molecule

Targets

Amyloid-beta aggregate (N-terminal epitope)

Beyond the preview

Go deeper on Aβ-SM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aβ-SM.

Explore the full profile